TABMELT
DEAD

Serial Number

87718255

Owner

Sentar Pharmaceuticals

First Use Date

Jan 3, 2018

Filing Date

Dec 12, 2017

Add to watchlist:

No watchlists yet
View on USPTO

TABMELT Trademark

Serial Number: 87718255 • Registration: 5771628

TABMELT is a trademark filed by Sentar Pharmaceuticals on December 12, 2017. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Sentar Pharmaceuticals (6 trademarks)

Irvine, CA 92614

Entity Type: 03

Trademark Details

Filing Date

December 12, 2017

Registration Date

June 4, 2019

First Use Anywhere

January 3, 2018

First Use in Commerce

May 5, 2018

Cancellation Date

December 19, 2025

Goods & Services

Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of dissolvable tablets that facilitate the delivery of pharmaceutical preparations; Nutraceuticals for use as a dietary supplement; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for skin care; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of hypercholesteremia; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of the cardiovascular system, the circulatory system, the endocrine system, the digestive system, the excretory system, the lymphatic system, the immune system, the muscular system, the nervous system, the renal system, the urinary system, the reproductive system, the respiratory system, and/or the skeletal system; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for knee cartilage regeneration; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical solutions used in dialysis; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, lipid lowering agents; Pharmaceuticals, namely, psychotropics; Vaccine preparations; Cardiovascular pharmaceuticals; Chemical preparations for pharmaceutical or medical purposes, namely, for the endocannabinoid; Human vaccine preparations; Oral vaccine preparations; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents

Filing History

CANCELLED SEC. 8 (6-YR)
Dec 19, 2025 C8..
WITHDRAWAL OF ATTORNEY GRANTED
Jul 25, 2023 WOAG
TEAS WITHDRAWAL OF ATTORNEY RECEIVED
Jul 25, 2023 WOAR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 6, 2022 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 6, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 6, 2022 REAP
REGISTERED-SUPPLEMENTAL REGISTER
Jun 4, 2019 R.SR
LAW OFFICE PUBLICATION REVIEW COMPLETED
Apr 30, 2019 PREV
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Apr 30, 2019 CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Apr 30, 2019 CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Apr 30, 2019 CHAN
NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED
Apr 25, 2019 AAUA
APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
Apr 24, 2019 CNTA
USE AMENDMENT ACCEPTED
Apr 24, 2019 IUAA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 20, 2019 TEME
AMENDMENT TO USE PROCESSING COMPLETE
Apr 20, 2019 AUPC
USE AMENDMENT FILED
Apr 20, 2019 IUAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 19, 2019 TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 19, 2019 TCCA
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 19, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 19, 2019 TROA
TEAS AMENDMENT OF USE RECEIVED
Apr 19, 2019 EAAU
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 17, 2019 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 17, 2019 REAP
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 30, 2018 GNRN
NON-FINAL ACTION E-MAILED
Oct 30, 2018 GNRT
NON-FINAL ACTION WRITTEN
Oct 30, 2018 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 10, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 10, 2018 CRFA
ASSIGNED TO LIE
Oct 2, 2018 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 20, 2018 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 22, 2018 GNRN
NON-FINAL ACTION E-MAILED
Mar 22, 2018 GNRT
NON-FINAL ACTION WRITTEN
Mar 22, 2018 CNRT
ASSIGNED TO EXAMINER
Mar 22, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 22, 2017 NWOS
NEW APPLICATION ENTERED
Dec 15, 2017 NWAP